Format

Send to

Choose Destination
J Biomed Opt. 2012 Jan;17(1):016014. doi: 10.1117/1.JBO.17.1.016014.

Monitoring early tumor response to drug therapy with diffuse optical tomography.

Author information

1
Columbia University, New York, Department of Biomedical Engineering, New York, New York 10027, USA.

Abstract

Although anti-angiogenic agents have shown promise as cancer therapeutics, their efficacy varies between tumor types and individual patients. Providing patient-specific metrics through rapid noninvasive imaging can help tailor drug treatment by optimizing dosages, timing of drug cycles, and duration of therapy-thereby reducing toxicity and cost and improving patient outcome. Diffuse optical tomography (DOT) is a noninvasive three-dimensional imaging modality that has been shown to capture physiologic changes in tumors through visualization of oxygenated, deoxygenated, and total hemoglobin concentrations, using non-ionizing radiation with near-infrared light. We employed a small animal model to ascertain if tumor response to bevacizumab (BV), an anti-angiogenic agent that targets vascular endothelial growth factor (VEGF), could be detected at early time points using DOT. We detected a significant decrease in total hemoglobin levels as soon as one day after BV treatment in responder xenograft tumors (SK-NEP-1), but not in SK-NEP-1 control tumors or in non-responder control or BV-treated NGP tumors. These results are confirmed by magnetic resonance imaging T2 relaxometry and lectin perfusion studies. Noninvasive DOT imaging may allow for earlier and more effective control of anti-angiogenic therapy.

PMID:
22352664
PMCID:
PMC3380816
DOI:
10.1117/1.JBO.17.1.016014
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Society of Photo-Optical Instrumentation Engineers Icon for PubMed Central
Loading ...
Support Center